therapeutic action: Potential antidepressant effects

Meditation, psychedelics, and brain connectivity: A randomized controlled resting-state fMRI study of N,N-dimethyltryptamine and harmine in a meditation retreat

mycolabadmin

Researchers studied how meditation combined with a psychedelic compound called DMT affects the brain. They scanned 40 experienced meditators before and after a 3-day retreat, with some receiving the psychedelic and others a placebo. While meditation alone reduced connections between different brain networks, the psychedelic enhanced certain connections, suggesting the two practices may complement each other in promoting mental health.

Read More »

Psychedelics: Safety and Efficacy

mycolabadmin

This paper reviews scientific research on psychedelic drugs like LSD and psilocybin that are being studied for treating depression and PTSD. While some research claims these drugs are beneficial, many studies have serious flaws including hiding negative side effects and being influenced by money from pharmaceutical companies. The author concludes that we need much better research before these drugs can be safely approved for medical use.

Read More »

4-Hydroxy-N,N-diisopropyltryptammonium hydrofumarate: Crystal Structure of a Synthetic Psychedelic

mycolabadmin

Scientists have determined the three-dimensional crystal structure of 4-HO-DiPT, a synthetic compound related to psilocin found in magic mushrooms. This is the first crystal structure of this specific compound and provides important structural information for understanding how it works. A related version of this compound is currently being tested in clinical trials for treating postpartum depression and other mood disorders.

Read More »

Scalable Hybrid Synthetic/Biocatalytic Route to Psilocybin

mycolabadmin

Researchers developed a new method to manufacture psilocybin, a promising therapeutic compound from magic mushrooms being tested to treat depression. Instead of using toxic chemicals, they replaced a difficult chemical step with an enzyme from the mushroom itself called PsiK. This approach produced gram amounts of pure psilocybin efficiently and could eventually lower costs for future medical use.

Read More »

Evaluation of the Indazole Analogs of 5-MeO-DMT and Related Tryptamines as Serotonin Receptor 2 Agonists

mycolabadmin

Researchers synthesized new drug candidates based on psychedelic molecules like 5-MeO-DMT, replacing the indole core with indazole scaffolds to potentially improve drug properties. While the lead compound VU6067416 showed excellent potency for serotonin receptors and favorable pharmacokinetics, it also activated 5-HT2B receptors strongly, raising safety concerns about heart problems. The study highlights the challenge of developing selective serotonin drugs and emphasizes the need for rigorous safety testing of psychedelic-based therapeutics.

Read More »
Scroll to Top